Compare Norfolk Southern Corporation (NSC) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Pfizer Inc — how do they compare? Norfolk Southern Corporation trades at $317.24 (market cap $70.35B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 2.3× Norfolk Southern Corporation's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Pfizer Inc for 158 Days on average.
| NSC | PFE | |
|---|---|---|
Market Cap | $70.35B | $159.59B |
Volume | 825,542 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $352.98 | $29.02 |
52-Week Low | $278.19 | $23.67 |
Typical Hold Time | 33 Days | 158 Days |
Enterprise Value | $85.89B | $211.09B |
Dividend Yield | 1.72% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $313.20, down 0.98% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.52 exceeding expectations by 6%. Valuation metrics include P/E of 26.72 and ROE of 16.97%, while the proposed Union Pacific merger progresses through regulatory review. Cash flow trends show operational strength with $4.36B from operations in 2025.
Outlook remains constructive with 43.75% analyst buy ratings and $361.86 consensus target offering 15.5% upside. Key risks include merger approval uncertainty and fuel cost pressures. The combination creates transcontinental railroad opportunities but faces STB regulatory hurdles. Earnings on October 22, 2026 will be critical for near-term direction.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
